NCT00089466View on ClinicalTrials.gov

Safety and Activity of the Oral HIV Entry Inhibitor AMD11070 in HIV Infected Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

June 30, 2006

Study Completion Date

January 31, 2009

Conditions
HIV Infections
Interventions
DRUG

AMD11070

AMD11070 taken daily. Dosage dependent on arm.

Trial Locations (3)

30308

The Ponce de Leon Ctr. CRS, Atlanta

35924-2050

Alabama Therapeutics CRS, Birmingham

46202-5250

Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis

All Listed Sponsors
collaborator

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NETWORK

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00089466 - Safety and Activity of the Oral HIV Entry Inhibitor AMD11070 in HIV Infected Patients | Biotech Hunter | Biotech Hunter